Post Treatment Care After Chemical Peel or Laser Resurfacing

Early Phase 1

Withdrawn

• Conditions: Chemical Peel
• Interventions: Drug: Aquaphor; Drug: HP828-101

• Registration Number: NCT01135290
• Lead Sponsor: Healthpoint

Brief Summary

This study tests two different approaches to the resolution of facial skin resurfacing.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-06
• Study First Submitted: 2010-06-01
• Study First Submitted QC: 2010-06-01
• Study First Posted: 2010-06-02
• Primary Completion: 2010-10
• Study Completion: 2010-10
• Status Verified: 2013-09
• Last Update Submitted: 2013-09-30
• Last Update Posted: 2013-10-01

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• The informed consent document and photography release must be read, signed, and dated by the subject or the subject's legally authorized representative before conducting any study procedures or exams. In addition, the informed consent and photography release document must be signed and dated by the individual who consents the subject before conducting Visit 1. A photocopy of the signed informed consent document must be provided to the subject, and the original signed document placed in the subject's chart.

• Subjects 18 years of age or older, scheduled to undergo either a medium chemical peel with 35% TCA or a laser resurfacing. Subjects may be of either sex and of any race or skin type provided that their skin color, in the opinion of the Investigator, will not interfere with the study assessments.

• Women of child-bearing potential (those who are not premenarchal, not surgically sterilized [hysterectomy or bilateral oophorectomy], or not post-menopausal) may participate in the study if they meet all of the following conditions:

  • they are not breast feeding
  • undertake a pregnancy test, which must be negative
  • they do not intend to become pregnant during the study
  • they are using adequate birth control methods and they agree to continue using those methods for the duration of the study

Adequate birth control methods are defined as: hormonal-topical, oral, implantable, or injectable contraceptives; mechanical-spermicide in conjunction with a barrier such as a condom or diaphragm; IUD; or, surgical sterilization of partner. For non-sexually active females, abstinence may be regarded as an adequate method of birth control; however, if the subject becomes sexually active during the study, she must agree to use an adequate birth control method as described above for the remainder of the study.

NOTE: Women who have had a bilateral tubal ligation are not considered to have been surgically sterilized and must agree to the conditions as specified above.

• Willing and able to make all required study visits.
• Able to follow instructions.
• Undergo a medium grade chemical peel or fractional resurfacing.

Exclusion Criteria

• Contraindications or hypersensitivity to the use of the study medications or their components (e.g., balsam of Peru, castor oil, or phenoxyethanol).
• Therapy with another investigational agent within thirty (30) days of Visit 1, or during the study.
• Have taken anticoagulants (blood thinners, including aspirin) within two weeks.
• Current smoker.
• Use of oral isotretinoin during the past 12 months, systemic steroids, topical retinoids, or topical corticosteroids within the month prior to the study.
• Have any congenital skin disorder which affects keratinocytes, elastin, or collagen.
• Have any dermatologic disease which may be aggravated or provoked by the wounding procedure.
• Are at risk of keloid or hypertrophic scar formation based on personal or family history, or skin exam.
• Have any skin disorder which causes delayed healing.
• Have any systemic condition that would compromise skin healing.
• The Medical Monitor may declare any subject ineligible for a valid medical reason.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
B	Aquaphor	-
A	HP828-101	-

Primary Outcome Measures

Name	Time	Method
Physician and subject evaluation ratings of the signs and symptoms of facial skin during post-operative care.	84 Days

Trial Locations

Locations (1)

University of Texas Southwestern Medical Center; 🇺🇸 Dallas, Texas, United States